Must Read Articles

Study Shows Concentration of Intratumoral Payload Correlates with ADC Activity

A study published in the March 2018 edition of Molecular Cancer Therapeutics shows that, while antibody–drug conjugates or ADC...

Phase III ECHELON-1 Clinical Trial of Brentuximab Vedotin Meets Primary Endpoint – Demonstrates a...

Data from the Phase III ECHELON-1 clinical trial evaluating brentuximab vedotin (Adcetris®; Seattle Genetics | Takeda) as part of...

Market Trend: Cancer Immunotherapy Destined for Growth

According to data provided by Allied Market Research, the global cancer immunotherapy market is expected to grow to $117.14...

What Happens when the World of Pharma Returns to Frankfurt?

In October 2017 the 28th CPhI Worldwide returns to Frankfurt, Germany. This event takes place in a year where...

Simplifying the Development of Site-specific Antibody-drugs Conjugates

Research by Rice University scientists, supported by the National Science Foundation and the Robert A. Welch Foundation, shows the...

A Simple Approach to the Registration of Antibody Drug Conjugates

Over the last two decades, Antibody-drug Conjugates (ADC) have become a major area of interest for an expanded pipeline...

Registration of Antibody Drug Conjugates

Abstract      Antibody Drug Conjugates (ADC) are a rapidly expanding area of pharma company pipelines. They combine the targeting of...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Antibody-drug Conjugates: Intracellular Trafficking of New Anticancer Therapeutics

A new article, published by a team of writers including Muhammad Kalim, Jie Chen, and Shenghao Wang from the...
Manufacturing

Antibody Drug Conjugate Development: Keys to Rapid IND Submission and Approval

Antibody drug conjugates (ADCs) are a relatively new type of drug that combines the targeting ability of a biologic...

Sacituzumab govitecan (IMMU-132) Demonstrates Therapeutic Potential in the Treatment of Metastatic Solid Cancers

Two prominent cancer journals have published phase II clinical trial results with sacituzumab govitecan (IMMU-132; Immunomedics) in a total...

FEATURED RESOURCES